title: The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
abstract: Ingenol-3-angelate (Ing3A), extracted from Euphorbia peplus, is currently in clinical trials for eradicating basal cell carcinoma, actinic keratosis, and squamous cell carcinoma (SCC) in situ by topical application. Although structurally related to phorbol esters and a protein kinase C activator, topical Ing3A, but not phorbol 12-myristate 13-acetate (PMA), inhibited the growth of subcutaneous tumors derived from PAM212 (mouse SCC) and B16 (mouse melanoma). Ing3A and PMA both induced acute neutrophilic inflammation on mouse skin, but only Ing3A caused subcutaneous hemorrhage and vascular damage. Both Ing3A and PMA activated extracellular signal-regulated kinase 1/2 (ERK1/2) in epidermis, but Ing3A also activated ERK1/2 in skin dermal fibroblasts and endothelial cells. Pretreatment with topical cyclosporin A (CsA), verapamil, or XR9576, modulators of P-glycoprotein (P-gp), prevented Ing3A-induced hemorrhage but not neutrophil infiltration. CsA also impaired the anticancer activity of Ing3A, whereas the anti-inflammatory dexamethasone did not. Ing3A, but not PMA, blocked photoaffinity labeling of human P-gp with [(125)I]iodoaryazidoprazosin and inhibited P-gp-mediated drug resistance to HCT-15 cells. The intracellular levels of Ing3A were significantly lower in P-gp-expressing cells, and treatment with XR9576 increased the levels to those of cells that do not express P-gp, showing that Ing3A binds to and is transported by P-gp. Taken together, our results suggest that P-gp-mediated absorptive transport, dermal penetration, and vascular damage contribute to the anticancer activity of Ing3A in vivo.
authors.affiliation: Laboratory of Cancer Biology and Genetics, Laboratory of Cell Biology, and Confocal Core Facility, Center for Cancer Research, National Cancer Institute and NIH Chemical Genomics Center, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
authors.forename: Luowei
authors.initials: L
authors.lastname: Li
authors.forename: Suneet
authors.initials: S
authors.lastname: Shukla
authors.forename: Andrew
authors.initials: A
authors.lastname: Lee
authors.forename: Susan H
authors.initials: SH
authors.lastname: Garfield
authors.forename: David J
authors.initials: DJ
authors.lastname: Maloney
authors.forename: Suresh V
authors.initials: SV
authors.lastname: Ambudkar
authors.forename: Stuart H
authors.initials: SH
authors.lastname: Yuspa
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000287:Administration, Topical; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000493:pharmacokinetics / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism; D045744:Cell Line, Tumor; D004224:Diterpenes / Q000378:metabolism* / Q000493:pharmacokinetics / Q000494:pharmacology; D003875:Drug Eruptions / Q000201:enzymology / Q000209:etiology; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects / Q000201:enzymology; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D011485:Protein Binding; D011493:Protein Kinase C / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000201:enzymology; D012878:Skin Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: C486592:3-ingenyl angelate; C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D004224:Diterpenes; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate
references.citation: Biochim Biophys Acta. 2009 May;1794(5):860-71
references.pmid: 19285158
references.citation: Cancer Cell. 2005 May;7(5):411-23
references.pmid: 15894262
references.citation: Mol Cancer Ther. 2007 Jul;6(7):2092-102
references.pmid: 17620438
references.citation: Oncogene. 2006 Jan 19;25(3):378-86
references.pmid: 16158048
references.citation: Cancer Res. 1987 Jun 15;47(12):3174-9
references.pmid: 3107806
references.citation: Cancer Immunol Immunother. 2008 Aug;57(8):1241-51
references.pmid: 18265980
references.citation: Cancer Res. 2003 Oct 1;63(19):6547-55
references.pmid: 14559850
references.citation: Australas J Dermatol. 2009 Feb;50(1):16-22
references.pmid: 19178487
references.citation: J Invest Dermatol. 2001 Apr;116(4):541-8
references.pmid: 11286621
references.citation: Oncogene. 2003 Oct 20;22(47):7468-85
references.pmid: 14576852
references.citation: Cancer Res. 1980 Dec;40(12):4694-703
references.pmid: 7438101
references.citation: Cancer Res. 2004 Apr 15;64(8):2833-9
references.pmid: 15087400
references.citation: Nat Rev Clin Oncol. 2009 Sep;6(9):507-18
references.pmid: 19636328
references.citation: J Cell Physiol. 1995 Apr;163(1):105-14
references.pmid: 7896886
references.citation: Drug Metab Dispos. 2009 Feb;37(2):359-65
references.pmid: 18971320
references.citation: Nat Rev Cancer. 2008 Oct;8(10):743-54
references.pmid: 18813320
references.citation: Blood. 2005 Aug 15;106(4):1362-8
references.pmid: 15845901
references.citation: Carcinogenesis. 1989 Mar;10(3):531-40
references.pmid: 2924397
references.citation: Cancer Res. 1973 Mar;33(3):542-6
references.pmid: 4689903
references.citation: Am J Physiol. 1994 Sep;267(3 Pt 1):L223-41
references.pmid: 7943249
references.citation: J Immunol. 2005 Feb 1;174(3):1686-92
references.pmid: 15661932
references.citation: Mol Pharmacol. 2004 Mar;65(3):675-84
references.pmid: 14978246
references.citation: J Invest Dermatol. 2000 Jul;115(1):19-23
references.pmid: 10886502
references.citation: J Clin Invest. 2006 Oct;116(10):2757-66
references.pmid: 16964312
references.citation: J Invest Dermatol. 2008 Mar;128(3):643-54
references.pmid: 17882268
references.citation: J Natl Cancer Inst. 1973 Nov;51(5):1723-5
references.pmid: 4762943
references.citation: J Control Release. 2008 Nov 12;131(3):198-204
references.pmid: 18725258
references.citation: Cancer Res. 1981 May;41(5):1967-72
references.pmid: 7214365
references.citation: N Engl J Med. 2009 Sep 17;361(12):1202-5
references.pmid: 19726764
references.citation: Facial Plast Surg Clin North Am. 2009 Aug;17(3):309-24
references.pmid: 19698913
references.citation: Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59
references.pmid: 17428165
references.citation: J Biol Chem. 1993 Dec 15;268(35):26079-81
references.pmid: 8253722
references.citation: J Control Release. 2010 Feb 15;141(3):277-99
references.pmid: 19850095
references.citation: J Investig Dermatol Symp Proc. 2002 Dec;7(1):17-26
references.pmid: 12518788
references.citation: J Biol Chem. 1998 Nov 6;273(45):29995-30002
references.pmid: 9792720
references.citation: Mol Cell Biol. 1999 Dec;19(12):8547-58
references.pmid: 10567579
references.citation: Cancer Res. 2004 May 1;64(9):3243-55
references.pmid: 15126366
references.citation: Science. 1986 May 2;232(4750):643-5
references.pmid: 3457471
references.citation: Int J Pharm. 2005 Nov 23;305(1-2):2-12
references.pmid: 16246513
references.citation: J Invest Dermatol. 2005 Jan;124(1):28-37
references.pmid: 15654950
references.citation: Mol Cancer Ther. 2004 Dec;3(12):1651-8
references.pmid: 15634659
references.citation: Carcinogenesis. 1993 Feb;14(2):205-9
references.pmid: 8435862
references.citation: J Immunol. 2006 Dec 1;177(11):8123-32
references.pmid: 17114487
references.citation: Semin Immunopathol. 2007 Apr;29(1):3-14
references.pmid: 17621950